These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 37828728)
1. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates. Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728 [TBL] [Abstract][Full Text] [Related]
2. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Conilh L; Fournet G; Fourmaux E; Murcia A; Matera EL; Joseph B; Dumontet C; Viricel W Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33803327 [TBL] [Abstract][Full Text] [Related]
3. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Nakada T; Masuda T; Naito H; Yoshida M; Ashida S; Morita K; Miyazaki H; Kasuya Y; Ogitani Y; Yamaguchi J; Abe Y; Honda T Bioorg Med Chem Lett; 2016 Mar; 26(6):1542-1545. PubMed ID: 26898815 [TBL] [Abstract][Full Text] [Related]
4. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125 [TBL] [Abstract][Full Text] [Related]
5. Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors. Guo Y; Shen Z; Zhao W; Lu J; Song Y; Shen L; Lu Y; Wu M; Shi Q; Zhuang W; Qiu Y; Sheng J; Zhou Z; Fang L; Che J; Dong X Adv Sci (Weinh); 2024 Apr; 11(13):e2306309. PubMed ID: 38269648 [TBL] [Abstract][Full Text] [Related]
6. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker. Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272 [TBL] [Abstract][Full Text] [Related]
7. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Ogitani Y; Abe Y; Iguchi T; Yamaguchi J; Terauchi T; Kitamura M; Goto K; Goto M; Oitate M; Yukinaga H; Yabe Y; Nakada T; Masuda T; Morita K; Agatsuma T Bioorg Med Chem Lett; 2016 Oct; 26(20):5069-5072. PubMed ID: 27599744 [TBL] [Abstract][Full Text] [Related]
8. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates. Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988 [TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951 [TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class. Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286 [TBL] [Abstract][Full Text] [Related]
11. Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates. Petersen ME; Brant MG; Lasalle M; Das S; Duan R; Wong J; Ding T; Wu KJ; Siddappa D; Fang C; Zhang W; Wu AML; Hirkala-Schaefer T; Garnett GAE; Fung V; Yang L; Hernandez Rojas A; Lawn SO; Barnscher SD; Rich JR; Colombo R Mol Cancer Ther; 2024 May; 23(5):606-618. PubMed ID: 38354417 [TBL] [Abstract][Full Text] [Related]
12. A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy. Böhnke N; Berger M; Griebenow N; Rottmann A; Erkelenz M; Hammer S; Berndt S; Günther J; Wengner AM; Stelte-Ludwig B; Mahlert C; Greven S; Dietz L; Jörißen H; Barak N; Bömer U; Hillig RC; Eberspaecher U; Weiske J; Giese A; Mumberg D; Nising CF; Weinmann H; Sommer A Bioconjug Chem; 2022 Jun; 33(6):1210-1221. PubMed ID: 35658441 [TBL] [Abstract][Full Text] [Related]
13. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974 [TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker. Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650 [TBL] [Abstract][Full Text] [Related]
17. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma. Shi J; Jiao T; Guo Q; Weng W; Ma L; Zhang Q; Wang L; Zhang J; Chen C; Huang Y; Wang M; Pan R; Tang Y; Hu W; Meng T; Liu SH; Guo J; Kong Y; Meng X Cancer Res; 2023 Nov; 83(22):3783-3795. PubMed ID: 37668527 [TBL] [Abstract][Full Text] [Related]
18. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)]. Tsuchikama K Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230 [TBL] [Abstract][Full Text] [Related]
19. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]